Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

NCT02197247 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

PROCEDURE: Pharmacokinetic sampling - AZD9291
DRUG: Rifampicin
DRUG: AZD9291 tablet dosing
PROCEDURE: Pharmacokinetic sampling - rifampicin
PROCEDURE: Pharmacokinetic sampling - AZ5140 and AZ7550

Sponsor

AstraZeneca